Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development Advances AP-SA02 on a faster path to potential approval and patient access May 7, 2026 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatm

May 6, 2026 -- Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to DOC1021, the Company's first-in-class, patient-derived double-loaded dendritic cell investigational therapy, for the treatment of unresectable or metastatic cutaneous melanoma. Unresectable or metastatic cutaneous melanoma re

May 6, 2026 -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB ("Ribo", HKEX: 6938) today announced the achievement of a further milestone. This marks the third key milestone achieved in the research collaboration with Boehringer Ingelheim to discover novel therapies for liver disease, including metabolic dysfunction associated steatohepatitis (MASH). MASH is a serious and progressive form of fatty liver disease that can lead to fibrosis, cirrhosis, liver failure and liver ca

May 6, 2026 -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, today announced the completion of patient enrollment in the global Phase III pivotal multi-regional clinical trial (RESPOND-2, Study AP301-HP-03) of AP301, a novel fiber-iron-based phosphate binder, for the treatment of hyperphosphatemia. The trial was conducte

May 5, 2026 -- MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results from its Phase II clinical trial of QA102 in patients with intermediate dry age-related macular degeneration (AMD). Results of the study were presented in an oral presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 annual meeting in Denver, Colorado. Intermediate dry AMD is a

Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors May 05, 2026 -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced the presentation of Phase 2 clinical data highlighting the potential abscopal effects of the Company’s novel oncolytic peptide, VP-315 (ruxotemitide), in the treat

Leverages Locust Walk's global asset sourcing capabilities across the US, Asia, and Europe to co-found NewCos with drug originators Provides comprehensive support to accelerate and de-risk drug development through value-creating clinical and regulatory milestones May 5, 2026 -- Banyan BioInnovations announces its launch as an investment firm that identifies best or first in class clinical stage assets, forms NewCos around them, and provides experienced centralized support to accelerate drug dev

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN). “The Terns acquisition reflects Merck’s continued focus on science‑driven, value‑enhancing business development aimed at bringing meaningful innovation to patients,” said Robert M. Davis, chairman and chief executive officer, Merck. “We believe TERN‑701 has the potential to become a differentiated treatment

Regulatory Clearance in Spain Advances Randomized, Placebo-Controlled Study; Patients Show Meaningful Reductions in EGFR-Inhibitor Skin Toxicities with No Treatment Disruptions May 5, 2026 -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced that it has secured regulatory authorization in Spain for its Phase 2a CLEER Trial of HT-001, while concurrently reporting encouraging interim clinical results demonstrating meaningful efficacy and safety in

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today highlighted preclinical data for its lead candidate, EB-003, a dual 5-HT2A and 5-HT1B modulator, in which a single dose of EB-003 significantly reduced context-induced freezing behavior one hour post-dose (p < 0.05). These results indicate a rapid reduction in conditioned fear response in